Group 1 - The article discusses Mirum Pharmaceuticals, Inc. (MIRM) and its potential value driven by an iBAT inhibitor following a Phase 2 miss [2] - The author, Terry Chrisomalis, has extensive experience in the biotech sector and provides in-depth analysis through the Biotech Analysis Central service [2] - The Biotech Analysis Central service includes a library of over 600 biotech investing articles and a model portfolio of more than 10 small and mid-cap stocks [2] Group 2 - The article does not provide any specific financial data or performance metrics related to Mirum Pharmaceuticals or the biotech industry [1][3][4]

Group 1 - The article discusses Mirum Pharmaceuticals, Inc. (MIRM) and its potential value driven by an iBAT inhibitor following a Phase 2 miss [2] - The author, Terry Chrisomalis, has extensive experience in the biotech sector and provides in-depth analysis through the Biotech Analysis Central service [2] - The Biotech Analysis Central service includes a library of over 600 biotech investing articles and a model portfolio of more than 10 small and mid-cap stocks [2] Group 2 - The article does not provide any specific financial data or performance metrics related to Mirum Pharmaceuticals or the biotech industry [1][3][4]